The FDA issued a third complete response letter for ONS-5010/Lytenava, requesting confirmatory efficacy evidence for wet AMD treatment. Lytenava is an ophthalmic bevacizumab formulation, potentially ...
Both anti-VEGF and surgical treatments improve VA in AMD-related submacular hemorrhage, with no statistically significant difference between the two treatments. Anti-VEGF injections may be associated ...
Please provide your email address to receive an email when new articles are posted on . FORT LAUDERDALE, Fla. — In this Healio Video Perspective, Michael A. Singer, MD, discusses promising results for ...
Oraya Therapeutics Inc. announced today that leading ophthalmologists from three European countries presented patient results following one year after a single treatment with Oraya Therapy for wet age ...
Injection-free subgroup results demonstrated that a single intravitreal dose of 4D-150 without any supplemental anti-VEGF injections resulted in stable mean visual acuity that was equal to or higher ...
The companies have proposed a strategic partnership in which Ikarovec will continue to develop its IKAR-003 gene therapy using VectorBuilder's tech.
Burnley Express on MSN
Your guide to AMD - spotlighting the eye condition for February's Awareness Month
Age-Related Macular Degeneration (AMD) is the biggest cause of sight loss in the UK, affecting around 700,000 people. As ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback